Physician nonadherence with a hepatitis C screening program

Quality Management in Health Care

Volumn 23, Issue 1, 2014, Pages 1-9

  Southern, William N ^a   Drainoni, Mari Lynn ^b,c,d,f,g,h   Smith, Bryce D ⁱ   Koppelman, Elisa ^b,c,g,h   McKee, M Diane ^a   Christiansen, Cindy L ^b,c,g,h   Gifford, Allen L ^b,c,d,e,g,h   Weinbaum, Cindy M ⁱ   Litwin, Alain H ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d Department of Medicine ^*  (United States)

^e Division of General Medicine   (United States)

^f Section of Infectious Diseases   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Clinical practice patterns; community based participatory research; guideline adherence; hepatitis C; intervention studies; mass screening

Indexed keywords

ADULT; AGED; ANALYSIS OF VARIANCE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; INTERVENTION STUDY; MALE; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIMARY HEALTH CARE; PROGRAM EVALUATION; PROSPECTIVE STUDY; RISK ASSESSMENT; STANDARDS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TRENDS; YOUNG ADULT;

ADULT; AGED; AMBULATORY CARE FACILITIES; ANALYSIS OF VARIANCE; COHORT STUDIES; FEMALE; GUIDELINE ADHERENCE; HEPATITIS C; HUMANS; INCIDENCE; INTERVENTION STUDIES; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PROGRAM EVALUATION; PROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84891862797     PISSN: 10638628     EISSN: 15505154     Source Type: Journal    
DOI: 10.1097/QMH.0000000000000007     Document Type: Article

References (41)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
2. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1-39.
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-823.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
7. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
8. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
9. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
10. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
11. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50(6):1750-1755.
12. Culver DH, Alter MJ, Mullan RJ, Margolis HS. Evaluation of the effectiveness of targeted look back for HCV infection in the United States-interim results. Transfusion. 2000;40:1176-1181.
13. Gordon FD. Cost-effectiveness of screening patients for hepatitis C. Am J Med. 1999;107:36S-40S.
14. Shin A, Cho ER, Kim J, et al. Factors associated with awareness of infection status among chronic hepatitis B and C carriers in Korea. Cancer Epidemiol Biomarkers Prev. 2009;18:1894-1898.
15. Dubois F, Desenclos JC, Mariotte N, Goudeau A. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology. 1997;25:1490-1496.
16. EASL International Consensus Conference on Hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol. 1999;31(suppl 1):3-8.
17. Galmiche JP. French Consensus Conference on Hepatitis C: screening and treatment. Gut. 1998;42:892-898.
18. US Department of Veteran's Affairs. Hepatitis C Guidelines. Washington, DC: US Department of Veterans Affairs; 2011. 2- 8-2011.
19. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203-212.
20. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676-683.
21. Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med. 1994;149:S69-S76.
22. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2005;25:107-130.
23. Vashitz G, Meyer J, Parmet Y, Henkin Y, Peleg R, Gilutz H. Physician adherence to the dyslipidemia guidelines is as challenging an issue as patient adherence. Fam Pract. 2011;28(5):524-531.
24. Wetzels GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens. 2004;22:1849-1855.
25. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA. 2006;295:1912-1920.
26. Calvin JE, Roe MT, Chen AY, et al. Insurance coverage and care of patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med. 2006;145:739-748.
27. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458-1465.
28. Degos F. Hepatitis C and alcohol. J Hepatol. 1999;31(suppl 1):113-118.
29. Caldwell SH, Jeffers LJ, Ditomaso A, et al. Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am J Gastroenterol. 1991;86:1219-1223.
30. Weinstock HS, Bolan G, Reingold AL, Polish LB. Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases. JAMA. 1993;269:392-394.
31. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore-an analysis of 309 sex partnerships. J Infect Dis. 1995;171:768-775.
32. Gunn RA, Murray PJ, Brennan CH, Callahan DB, Alter MJ, Margolis HS. Evaluation of screening criteria to identify persons with hepatitis C virus infection among sexually transmitted disease clinic clients: results from the San Diego Viral Hepatitis Integration Project. Sex Transm Dis. 2003;30:340-344.
33. Kilbourne AM, McCarthy JF, Himelhoch S, Welsh D, Hauser P, Blow FC. Guideline-concordant hepatitis C virus testing and notification among patients with and without mental disorders. Gen Hosp Psychiatry. 2008;30: 495-500.
34. Himelhoch S, McCarthy JF, Ganoczy D, et al. Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. Psy-chosomatics. 2009;50:30-37.
35. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91:31-37.
36. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry. 2003;160:172-174.
37. Public Welfare: Subtitle A-DepartmentofHealth and Human Services, General Administrative Requirements. http://www.hhs.gov/ocr/hipaa/finalreg.html [2002 (45 C.F.R. Part 160) Available from http://www.hhs.gov/ocr/hipaa/finalreg.html]
38. Public Welfare: Subtitle A-DepartmentofHealth and Human Services, Security and Privacy. http://www.hhs.gov/ocr/hipaa/finalreg.html [2002 (45 C.F.R. Part 164, Subparts A and E) Available from http://www.hhs.gov/ocr/hipaa/ finalreg.html]
39. Hadley J, Mitchell JM, Sulmasy DP, Bloche MG. Perceived financial incentives, HMO market penetration, and physicians' practice styles and satisfaction. Health Serv Res. 1999;34:307-321.
40. Campion EW. A symptom of discontent. N Engl J Med. 2001;344:223-225.
41. Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health. 2003;93:635-641.